Retraction Note: MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via downregulation of GADD45α (Mol Cancer, (2015), 14, (190), 10.1186/s12943-015-0465-3);MiR-362-5p promotes the malignancy of chronic myelocytic leukaemia via down-regulation of GADD45aα

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Yang, Peng ^a   Ni, Fang ^a   Deng, Rui Qing ^a   Qiang, Guo ^a   Zhao, Hua ^a   Yang, Ming Zhen ^a   Wang, Xin Yi ^a   Xu, You Zhi ^a   Chen, Li ^a   Chen, Dan Lei ^a   Chen, Zhi Jun ^a   Kan, Li Xin ^a   Wang, Si Ying ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

CML; GADD45a ; JNK1 2; MiR 362 5p; Oncogene; P38

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; GADD45ALPHA PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; LIPOCORTIN 5; LUCIFERASE; MICRORNA; MICRORNA 362 5P; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; GADD45A PROTEIN, HUMAN; MIRN361 MICRORNA, HUMAN; NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOASSAY; BLOOD SAMPLING; CANCER CELL LINE; CARCINOGENICITY; CELL COUNTING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME ACTIVATION; ENZYME REGULATION; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE REAL TIME POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; K-562 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NUCLEAR PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84946564075     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-022-01573-1     Document Type: Erratum

References (52)

1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014update on diagnosis, monitoring, and management. Am J Hematol. 2014;89:547-56.
2. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014;165:273-86.
3. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, et al. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res. 2005;65:9436-44.
4. Zaccaria A, Tassinari A, Testoni N, Lauria F, Tura S, Algeri R, et al. Alternative BCR/ABL transcripts in chronic myeloid leukemia. Blood. 1990;76:1663-5.
5. Pane F, Mostarda I, Selleri C, Salzano R, Raiola AM, Luciano L, et al. BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients. Blood. 1999;94:2200-7.
6. Todoric-Zivanovic B, Marisavljevic D, Surace C, Cemerikic V, Markovic O, Krtolica K, et al. A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6;9)(p21;q34.1). Cancer Genet Cytogenet. 2006;166:180-5.
7. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008;111:1774-80.
8. Savage DG, Antman KH. Imatinib mesylate--a new oral targeted therapy. N Engl J Med. 2002;346:683-93.
9. Fava C, Kantarjian HM, Jabbour E, O'Brien S, Jain N, Rios MB, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009;113:5058-63.
10. Hehlmann R. How I treat CML blast crisis. Blood. 2012;120:737-47.
11. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522-31.
12. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515-24.
13. Kobayashi T, Lu J, Cobb BS, Rodda SJ, McMahon AP, Schipani E, et al. Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci U S A. 2008;105:1949-54.
14. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857-66.
15. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12:580-7.
16. Zhang X, Zeng J, Zhou M, Li B, Zhang Y, Huang T, et al. The tumor suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid leukemia. Mol Cancer. 2012;11:56.
17. Zhou M, Zeng J, Wang X, Guo Q, Huang T, Shen H, et al. MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1. J Transl Med. 2013;11:265.
18. Lopotova T, Zackova M, Klamova H, Moravcova J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res. 2011;35:974-7.
19. Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, et al. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica. 2010;95:1675-82.
20. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766-70.
21. Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z, et al. MicroRNA-362-5p promotes tumor growth and metastasis by targeting CYLD in hepatocellular carcinoma. Cancer Lett. 2015;356:809-18.
22. Amanullah A, Azam N, Balliet A, Hollander C, Hoffman B, Fornace A, et al. Cell signalling: cell survival and a Gadd45-factor deficiency. Nature. 2003;424:741. discussion 742.
23. Hoffman B, Liebermann DA. Gadd45 in modulation of solid tumors and leukemia. Adv Exp Med Biol. 2013;793:21-33.
24. Gupta M, Gupta SK, Balliet AG, Hollander MC, Fornace AJ, Hoffman B, et al. Hematopoietic cells from Gadd45a- and Gadd45b-deficient mice are sensitized to genotoxic-stress-induced apoptosis. Oncogene. 2005;24:7170-9.
25. Hoffman B, Liebermann DA. Gadd45 modulation of intrinsic and extrinsic stress responses in myeloid cells. J Cell Physiol. 2009;218:26-31.
26. Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood. 2006;107:4080-9.
27. Mancini M, Leo E, Aluigi M, Marcozzi C, Borsi E, Barbieri E, et al. Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor. Leuk Res. 2012;36:1028-34.
28. Zhu L, Somlo G, Zhou B, Shao J, Bedell V, Slovak ML, et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther. 2005;4:787-98.
29. Liebermann DA, Tront JS, Sha X, Mukherjee K, Mohamed-Hadley A, Hoffman B. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog. 2011;16:129-40.
30. Maia V, Sanz M, Gutierrez-Berzal J, de Luis A, Gutierrez-Uzquiza A, Porras A, et al. C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival. Cell Signal. 2009;21:1229-35.
31. Stein SJ, Baldwin AS. NF-kappaB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death. Oncogene. 2011;30:4557-66.
32. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem. 2004;279:25345-52.
33. Wu XP, Xiong M, Xu CS, Duan LN, Dong YQ, Luo Y, et al. Resveratrol induces apoptosis of human chronic myelogenous leukemia cells in vitro through p38 and JNK-regulated H2AX phosphorylation. Acta Pharmacol Sin. 2015;36:353-61.
34. Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, et al. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica. 2010;95:914-21.
35. Stoklosa T, Slupianek A, Datta M, Nieborowska-Skorska M, Nowicki MO, Koptyra M, et al. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance. Cell Cycle. 2004;3:1463-72.
36. Miyake Z, Takekawa M, Ge Q, Saito H. Activation of MTK1/MEKK4 by GADD45 through induced N-C dissociation and dimerization-mediated trans autophosphorylation of the MTK1 kinase domain. Mol Cell Biol. 2007;27:2765-76.
37. Zhu N, Shao Y, Xu L, Yu L, Sun L. Gadd45-alpha and Gadd45-gamma utilize p38 and JNK signaling pathways to induce cell cycle G2/M arrest in Hep-G2 hepatoma cells. Mol Biol Rep. 2009;36:2075-85.
38. Niehrs C, Schafer A. Active DNA demethylation by Gadd45 and DNA repair. Trends Cell Biol. 2012;22:220-7.
39. Tamura RE, de Vasconcellos JF, Sarkar D, Libermann TA, Fisher PB, Zerbini LF. GADD45 proteins: central players in tumorigenesis. Curr Mol Med. 2012;12:634-51.
40. Gupta SK, Gupta M, Hoffman B, Liebermann DA. Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation. Oncogene. 2006;25:5537-46.
41. Perugini M, Kok CH, Brown AL, Wilkinson CR, Salerno DG, Young SM, et al. Repression of Gadd45alpha by activated FLT3 and GM-CSF receptor mutants contributes to growth, survival and blocked differentiation. Leukemia. 2009;23:729-38.
42. Nymark P, Guled M, Borze I, Faisal A, Lahti L, Salmenkivi K, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer. Genes Chromosomes Cancer. 2011;50:585-97.
43. Ferraz C, Lorenz S, Wojtas B, Bornstein SR, Paschke R, Eszlinger M. Inverse correlation of miRNA and cell cycle-associated genes suggests influence of miRNA on benign thyroid nodule tumorigenesis. J Clin Endocrinol Metab. 2013;98:E8-16.
44. Hildesheim J, Belova GI, Tyner SD, Zhou X, Vardanian L, Fornace Jr AJ. Gadd45a regulates matrix metalloproteinases by suppressing DeltaNp63alpha and beta-catenin via p38 MAP kinase and APC complex activation. Oncogene. 2004;23:1829-37.
45. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, et al. Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999;97:575-86.
46. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther. 2007;15:2070-9.
47. McDermott AM, Heneghan HM, Miller N, Kerin MJ. The therapeutic potential of microRNAs: disease modulators and drug targets. Pharm Res. 2011;28:3016-29.
48. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2011;80:193-208.
49. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198-201.
50. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011;71:7608-16.
51. Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice--brief report. Arterioscler Thromb Vasc Biol. 2013;33:1973-7.
52. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood. 2011;118:3634-44.